Citigroup
KLRS icon

Citigroup’s Kalaris Therapeutics KLRS Stock Holding History

Citigroup’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3 Buy
+1
New +$4 ﹤0.01% 5898
2026
Q2 		– Sell
-8,703
Closed -$50.2K – 6388
2026
Q1 		$50.2K Buy
8,703
+8,702
+870,200% +$77.2K ﹤0.01% 4528
2025
Q4 		$8 Hold
1
– – ﹤0.01% 5830
2025
Q3 		$6 Buy
+1
New +$3 ﹤0.01% 5982
2025
Q1 		– Sell
-7
Closed -$66 – 6065
2024
Q4 		$66 Sell
7
-36
-84% -$545 ﹤0.01% 5706
2024
Q3 		$800 Sell
43
-289
-87% -$5.06K ﹤0.01% 5458
2024
Q2 		$5.53K Sell
332
-122
-27% -$2.15K ﹤0.01% 5246
2024
Q1 		$7.89K Buy
454
+129
+40% +$2.1K ﹤0.01% 5251
2023
Q4 		$5.08K Buy
325
+259
+392% +$10.2K ﹤0.01% 5331
2023
Q3 		$3.28K Sell
66
-608
-90% -$41.4K ﹤0.01% 4834
2023
Q2 		$52.7K Buy
674
+563
+507% +$53.5K ﹤0.01% 4612
2023
Q1 		$10.1K Sell
111
-2
-2% -$255 ﹤0.01% 4726
2022
Q4 		$13.3K Buy
113
+1
+0.9% +$170 ﹤0.01% 4740
2022
Q3 		$20K Sell
112
-167
-60% -$26K ﹤0.01% 4754
2022
Q2 		$25K Buy
279
+17
+6% +$1.78K ﹤0.01% 4879
2022
Q1 		$41K Sell
262
-2,234
-90% -$446K ﹤0.01% 4817
2021
Q4 		$743K Buy
2,496
+1,100
+79% +$510K ﹤0.01% 3523
2021
Q3 		$804K Sell
1,396
-3,497
-71% -$1.62M ﹤0.01% 3252
2021
Q2 		$2.22M Buy
4,893
+816
+20% +$421K ﹤0.01% 2590
2021
Q1 		$2.19M Buy
4,077
+3,812
+1,438% +$3.2M ﹤0.01% 2429
2020
Q4 		$234K Buy
265
+228
+616% +$175K ﹤0.01% 4875
2020
Q3 		$24K Buy
+37
New +$25.3K ﹤0.01% 6064

Other funds holding KLRS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
WealthTrust Asset Management
WealthTrust Asset Management Destin, Florida $181M AUM 17.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Strengthening Families & Communities LLC
Strengthening Families & Communities LLC Boston, Massachusetts $459M AUM 29.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Citigroup's KLRS Position: Q3 2026 in Review

Citigroup opened a new position in Kalaris Therapeutics (KLRS) in Q3 2026: 1 share worth $3. The stake represents ﹤0.01% of the portfolio and ranks #5898 among its holdings. This is a return to the name: Citigroup previously reported a position in KLRS as recently as Q1 2026.

Citigroup first reported a position in KLRS in Q3 2020 and has held it in 22 quarters since. The position peaked at $2.22M in Q2 2021. 8 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Citigroup held 1 share of Kalaris Therapeutics worth $3 as of Q3 2026.
  • Kalaris Therapeutics was a new Citigroup position in Q3 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5898 holding.
  • Citigroup first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Citigroup's Kalaris Therapeutics position peaked at $2.22M in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.